I am a research supervisor with 30+ years experience in Laboratory Management and Molecular Biology. As an alumni of the Jim Kaper laboratory, I helped to develop the first FDA approved oral Vibrio cholera vaccine, CVD103HgR, now known as Vaxchora (PaxVax). Since joining the Rasko lab in 2014, I have been involved in antibiotic resistance among Escherichia coli, Klebsiella pneumonia and Acinetobacter baumannii. Other studies include the metagenomics and metatranscriptomics of the human fecal microbiome during Enterotoxigenic E. coli (ETEC) or V. cholerae infection. When I’m not in the lab I enjoy biking, cooking and home improvement projects.
Selected Publications:
- H-NST induces LEE expression and the formation of attaching and effacing lesions in enterohemorrhagic Escherichia coli. Levine JA, Hansen AM, Michalski JM, Hazen TH, Rasko DA, Kaper JB. PLoS One. 2014 Jan 21;9(1):e86618. doi: 10.1371/journal.pone.0086618. PMID:24466172
- An in vivo expression technology screen for Vibrio cholerae genes expressed in human volunteers. Lombardo MJ, Michalski J, Martinez-Wilson H, Morin C, Hilton T, Osorio CG, Nataro JP, Tacket CO, Camilli A, Kaper JB. Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18229-34. PMID:17986616
- Identification and characterization of the locus for diffuse adherence, which encodes a novel afimbrial adhesin found in atypical enteropathogenic Escherichia coli. Scaletsky IC, Michalski J, Torres AG, Dulguer MV, Kaper JB. Infect Immun. 2005 Aug;73(8):4753-65.
- The Vibrio cholerae genome contains two unique circular chromosomes. Trucksis M, Michalski J, Deng YK, Kaper JB. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14464-9. PMID:9826723
- CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Michalski J, Galen JE, Fasano A, Kaper JB. Infect Immun. 1993 Oct;61(10):4462-8. PMID: 8406837